Live Biotherapeutic Products (LBPs) are transforming therapeutic development, with clinical programs expanding across gastrointestinal disorders, metabolic disorders, immunology, oncology, and rare conditions. Unlike conventional pharmaceuticals, however, LBPs contain living microorganisms. Their clinical performance depends on maintaining defined quality attributes such as identify, purity, potency, stability, and, where applicable, viability throughout manufacturing, storage, distribution, and administration.
This fundamental distinction changes the role of clinical supply chain management. For traditional investigational products, the objective is to ensure the correct product reaches the correct patient at the correct time. For LBPs, sponsors must also demonstrate that the product administered remains representative of investigational product originally characterized, released, and reviewed by regulators. Temperature excursion, customs delays, packaging failures, or improper handling at a clinical sites may compromise critical quality attributes before administration. Consequently, clinical supply chain oversight is no longer simply a logistics function. It is an extension of Chemistry, Manufacturing and Controls (CMC), Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), Good Clinical Practice (GCP), and Quality Risk Management.
As microbiome therapeutics continue to mature, sponsors that integrate supply chain strategy early in development will be better positioned to reduce operational risk, maintain regulatory compliance, protect patient safety, and generate reliable clinical evidence.
The microbiome field has evolved rapidly over the past decade. What began primarily as probiotic research has expanded into sophisticated therapeutic platforms that include defined microbial consortia, engineered bacteria, recombinant microorganisms, and precision microbiome medicine.
Recent commercial products have demonstrated that microbiome-based therapeutics are no longer experimental concepts but an emerging class of regulated biological medicine.
Unlike conventional pharmaceuticals, however, LBPs remain biologically active throughout their lifecycle. Their therapeutic performance depends on preserving critical quality attributes established during product development. Distribution therefore becomes part of product quality rather than simply product delivery.
This distinction fundamentally changes how sponsors should design and oversee clinical supply chains.
Many organizations entering microbiome therapeutics have prior experience developing probiotic or Natural Health Products (NHPs). Although both contain living microorganisms, the regulatory expectations differ substantially.
Health Canada’s Probiotics Monograph illustrates that even probiotic NHPs require species and strain identification, quantification of viable organisms, and assessment of safety characteristics such as antibiotic resistance and toxigenic potential.
Therapeutic LBPs, however, are developed as regulated medicinal products intended to prevent, treat, or cure disease. As such, they require comprehensive product characterization, validated manufacturing processes, stability programs, clinical evidence, and robust quality systems.
Simply stated:
This distinction influences every aspect of clinical development.
For conventional pharmaceuticals, product quality is largely established during manufacturing and confirmed through release testing.
For LBPs, manufacturing alone cannot ensure product quality.
Critical Quality Attributes (CQAs) may be influenced during:
Potential consequences include:
A shipment may remain fully accounted for while no longer representing the product originally characterized within the CMC dossier.
Accordingly, regulators increasingly view the clinical supply chain as part of the overall pharmaceutical quality system rather than an isolated logistics activity.
Although product CQAs vary, sponsors should establish controls to preserve attributes such as:
Each supply chain activity should be evaluated using a Quality Risk Management approach: Can this activity affect a Critical Quality Attribute?
If the answer is yes, appropriate preventive controls, monitoring, deviation management, and corrective actions should already be defined.
Although regulatory pathways differ, FDA and Health Canada apply similar quality principles to therapeutic live microorganisms.
The FDA has published dedicated guidance describing CMC expectations for early clinical trials involving LBPs, Emphasizing comprehensive characterization, manufacturing consistency, stability, potency, and product specifications.
Health Canada regulates therapeutic microorganisms within its biologics framework under the Food and Drugs Act and Food and Drug Regulations. While no LBP-specific guidance currently exists, sponsors are expected to demonstrate comparable levels of manufacturing control, product characterization, stability, and quality oversight.
For multinational clinical trials, implementing the more comprehensive documentation and quality controls recommended in FDA guidance generally supports regulatory expectations across both jurisdictions.
1. Environmental Exposure
Many LBPs contain microorganisms sensitive to oxygen, humidity, or moisture ingress.
Validated packaging systems, container closure integrity testing, barrier materials, inert atmospheres where appropriate, and environmental monitoring all contribute to preserving product quality throughout distribution.
2. Temperature Excursions
Temperature remains one of the greatest operational risks.
Depending on formulation, LBPs may require refrigerated, frozen, ultra-low temperature, or cryogenic storage.
Sponsors should implement:
Cold chain management is fundamentally a quality control process rather than a transportation exercise.
3. International Distribution
Global studies introduce additional risks including:
Transportation routes should therefore be qualified using risk-based assessments rather than assuming every shipment will follow an ideal pathway.
4. Clinical Site Handling
Product quality remains vulnerable after delivery.
Clinical sites should demonstrate:
Well-designed transportation can still fail if product handling at the site is inadequate.
5. Inventory Management
Many LBPs combine limited shelf lives with lengthy manufacturing lead times.
Dynamic forecasting using Interactive Response Technology (IRT/RTSM) enables sponsors to balance manufacturing campaigns, enrollment, regional inventory, and product expiry while minimizing waste and reducing stockout risk.
Clinical supply oversight should be integrated into the sponsor’s overall Quality Management System using internationally recognized Quality Risk Management principles.
Every stage of distribution should address three fundamental questions:
This risk-based approach supports inspection readiness while ensuring quality oversight extends beyond manufacturing.
Successful LBP trials require close collaboration among sponsors, CROs, manufacturers, depots, logistics providers, and clinical sites.
Best practices include:
Integrate Supply Chain During CMC Development
Supply strategy be Established while formulation, packaging, stability studies, and release specifications are still being developed.
Develop Quality Agreements
Responsibilities should be clearly defined between all parties involved in manufacturing and distribution, including excursion management, shipment release, documentation, product accountability, and deviation reporting.
Build Regional Distribution Networks
Strategically positioned depots reduce transportation time, minimize customs-related delays, and improve supply resilience.
Train Clinical Sites
Training should extend beyond storage requirements to include product preparation, accountability, deviation reporting, quarantine procedures, and product returns.
Leverage Digital Technologies
Modern Interactive Response Technology/ Randomization and Trial Supply Management (IRT/RTSM) platforms combined with shipment monitoring systems provide real-time visibility into inventory, product expiry, shipment status, and patient demand, supporting proactive supply decisions.
Before initiating an LBP clinical trial, sponsors should be able to answer “yes” to each of the following:
✓ Have microbial strains been fully characterized?
✓ Are Critical Quality Attributes (CQAs) clearly defined?
✓ Do release specifications appropriately evaluate potency and, where applicable, viability?
✓ Are stability studies sufficient to support proposed storage and transportation conditions?
✓ Have shipping systems qualified?
✓ Are acceptable temperature excursion criteria scientifically justified?
✓ Is complete chain of identity and chain of custody maintained?
✓ Have depot and clinical sites been qualified?
✓ Have site personnel received product-specific handling training?
✓ Is inventory forecasting continuously updated?
✓ Can every investigational unit be fully reconciled at study close?
If any answer is “no”, additional planning may reduce both regulatory and operational risk before study initiation.
The next generation of microbiome therapeutics, including genetically engineered microorganisms, recombinant bacterial platforms, personalized microbiome therapies, and synthetic microbial consortia, will further increase supply chain complexity.
Further regulatory expectations are likely to place greater emphasis on lifecycle quality management, digital supply chain visibility, environmental risk assessment, manufacturing standardization, and international harmonization.
Organizations that establish robust, risk-based clinical supply systems today will be better positioned to support increasingly complex biological therapies tomorrow.
For LBPs, product quality does not end when manufacturing is complete.
Every storage condition, shipment, depot transfer, clinical site, and patient interaction has the potential to influence the quality attributes that underpin product performance.
Clinical supply chain oversight must therefore be viewed as an integral component of the pharmaceutical quality system, closely aligned with CMC, GMP, GDP, GCP, and Quality Risk Management.
By integrating supply chain strategy early in development, protecting critical quality attributes throughout distribution, and fostering strong collaboration between sponsors, CROs, manufacturers, and clinical sites, organizations can reduce operational risk, satisfy regulatory expectations, protect patient safety, and generate clinical evidence that accurately reflects the therapeutic potential of these innovative medicines.
For LBPs, the supply chain is no longer simply about moving product, it is about preserving product quality from manufacturing to patient.
Clinical supply chain oversight for Live Biotherapeutic Products requires expertise spanning regulatory affairs, Chemistry, Manufacturing and Controls (CMC), quality assurance, clinical operations, and investigational product management. Success depends not only on delivering product to clinical sites, but also on maintaining microbial viability, ensuring product consistency, and preserving critical quality attributes throughout the clinical trial.
At dicentra, we understand the unique challenges associated with probiotic and microbiome-based therapeutics. As a boutique Contract Research Organization (CRO) with extensive experience supporting probiotic clinical research, we help sponsors navigate the operational and regulatory complexities of developing live microorganism-based products.
Whether you’re preparing an early-phase clinical trial, developing a regulatory strategy, managing investigational product logistics, or planning a multinational LBP program, our multidisciplinary team can help design a clinical supply strategy that supports both regulatory compliance and study success.
Contact dicentra to learn how we can support your next Live Biotherapeutic Product clinical trial.